Industry
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 12:45 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 1:40 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 10:28 am
Portfolio Pulse from Benzinga Newsdesk
February 15, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Insights
December 20, 2023 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
December 18, 2023 | 3:37 pm
Portfolio Pulse from Benzinga Newsdesk
December 08, 2023 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
December 08, 2023 | 12:47 pm
Portfolio Pulse from Benzinga Newsdesk
December 05, 2023 | 3:23 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.